Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9.

View in: PubMed

subject areas

Adolescent
Adrenal Cortex Hormones
Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
CD3 Complex
Colitis, Ulcerative
Dose-Response Relationship, Drug
Drug Resistance
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies
Survival Rate
Treatment Outcome
Young Adult

authors with profiles

Stephen B. Hanauer